Background There is evidence that chronic inflammation may promote atherosclerotic disease.
We tested the hypothesis that acute infection and vaccination increase the short-term risk …

Background: Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are common diagnoses in
patients attending chest clinics, but little is known about the epidemiology of these diseases. …

ContextIn vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not
COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without …

Despite the considerable progress in the classification of the idiopathic interstitial pneumonias
(IIPs), the lack of an international standard has resulted in variable and confusing …

Cryptogenic fibrosing alveolitis has been reported to be associated with an increased risk of
lung cancer. However, it has recently become apparent that cigarette smoking may be a risk …

As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a
need to coordinate data on incidence and mortality globally. This study aims to systematically …

Background Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX),
which leads to suppression of COX-1-mediated production of gastrointestinal-protective …

Objective Patients with COPD are at risk for cardiovascular events. This is attributed to
increased systemic inflammation. The course of COPD is punctuated by exacerbations, which …

Positive emotional activities have been suggested as modifiers of neuroendocrine hormones
involved in the classical stress response. To detect changes in these components during a …

Objective To investigate the efficacy and safety of SC‐58635 (celecoxib), an antiinflammatory
and analgesic agent that acts by selective cyclooxygenase 2 (COX‐2) inhibition and is not …